summary-of-results-healthcare-consumer-survey-18-november-2016
Market Inquiry into the Private Healthcare Sector
The Commission is conducting a market inquiry in the private healthcare sector in terms of Chapter 4A of the Competition Act, 89 of 1998 (as amended) (the Act) and in keeping with the purpose and functions of the Commission set out in section 2 and section 21 of the Act respectively.
Section 21 of the Act calls on the Commission to, inter alia, “implement measures to increase market transparency” and “advise, and receive advice from, any regulatory authority”. In order to fulfil these functions, and in line with the purpose of the Act, Chapter 4A of the Act enables the Commission to conduct market inquiries in respect of the “general state of competition in a market for particular goods and services, without necessarily referring to the conduct or activities of any particular name firm”.
A market inquiry is thus a general investigation into the state, nature and form of competition in a market, rather than a narrow investigation of a specific conduct by any particular firm. The Commission has initiated an inquiry into the private healthcare sector because it has reason to believe that there are features of the sector that prevent, distort or restrict competition.
The Commission further believes that conducting this inquiry will assist in understanding how it may promote competition in the healthcare sector, in furtherance of the purpose of the Act.
LATEST :
Latest Notice: Agenda : Health Outcome Measurement and Reporting Seminar
Health Outcomes Quality and Reporting Seminar Submissions
Inventory of Submissions for Health Outcome Measurement and Reporting
Discussion document and call for submissions
Notice to Stakeholders : Changes to the Health Market Inquiry (HMI) Administrative Timetable
Notice to Stakeholders : OECD WHO working paper No 85
Research Note Cross Ownership and Cross Directorships in the South African Private Healthcare sector
Notice to Stakeholders – 19 May 2017
Notice to Stakeholders – 24 April 2017
Panel position on the OECD / WHO working paper No 85
Publication of reports as set out in the Revised Administrative Timetable: 28 February 2017
Proposed approach emanating from stakeholder meeting held on 7 February 2017
DOCUMENTS FOR PUBLIC COMMENTS
Report on Analysis of Claims Data Initial Cost Attribution Analysis
Analysis of Medical Schemes Claims Data
Market Definition for Financing of Healthcare
Summary of Consumer Survey Results
Methodology Paper: Market Power of Health Facilities
TERM OF REFERENCE
Government Gazette Amended Terms of Reference
Revised Administrative Timetable
PRESENTATIONS AND REPORTS
Scenarium Report for Mediclinic
NOTICE TO STAKEHOLDERS
Access to Confidential Information held by the Health Market Inquiry meeting with stakeholders
Notice: Access to confidential Information
Notice to Stakeholders: Publication of Provisional Report
Notice to Stakeholders : Invitation to Seminar
Supplementary Guideline No. 3 (Published)
2016 PUBLIC HEARINGS
Schedule for Continuation of Set 1 Public Hearings, Durban
Notice: Continuation of Public Hearings – 12 April 2016
Notice: Revision of Programme for Public Hearings – 17 March 2016
Week 6 Public Hearings – 17 to 19 May 2016, Olive Convention Centre, Durban
Week 5 Public Hearings – 03 to 05 May 2016, HMI Offices, Pretoria
Week 4 Public Hearings – 08 to 11 March 2016, CTICC, Cape Town
Week 3 Public Hearings – 1 to 3 March 2016, CTICC, Cape Town
Week 2 Public Hearings – 23 to 25 February 2016, HMI Offices
Week 1 Public Hearings – 16 to 18 February 2016, CSIR
SCHEDULE FOR SET 1 PUBLIC HEARINGS (subject to revision)
In This Section:
- Public Hearings
- Administrative Timetable
- Notices
- Call for Submissions
- Statement of Issues and Administrative Guidelines for Participation
- Panel Members
- Terms of Reference
- Health Inquiry Forms
- Healthcare Market Background Papers
- Glossary of Terms
- Profitability Analysis Methodology
- Re-Opening Of Participants To Make Oral Submissions At The Public Hearings Of The Health Market Inquiry.
- Q&A with Health Care Inquiry Director: Adv Clint Oellermann
